Related Experiment Video
Updated: Jun 23, 2025
The Monoiodoacetate Model of Osteoarthritis Pain in the Mouse
Published on: May 16, 2016
Uncoupling the CRMP2-CaV2.2 interaction reduces pain-like behavior in a preclinical osteoarthritis model
Heather N Allen1, Sara Hestehave2, Paz Duran2
1Department of Pharmacology & Therapeutics, University of Florida College of Medicine, Gainesville, Florida 32610, USA.
Abstract:
Osteoarthritis (OA) represents a significant pain challenge globally, as current treatments are limited and come with substantial and adverse side effects. Voltage-gated calcium channels have proved to be pharmacologically effective targets, with multiple FDA-approved CaV2.2 modulators available for the treatment of pain. Although effective, drugs targeting CaV2.2 are complicated by the same obstacles facing other pain therapeutics-invasive routes of administration, narrow therapeutic windows, side effects, and addiction potential. We have identified a key regulator of CaV2.2 channels, collapsing response mediator protein 2 (CRMP2), that allows us to indirectly regulate CaV2.2 expression and function. We developed a peptidomimetic modulator of CRMP2, CBD3063, that effectively reverses neuropathic and inflammatory pain without negative side effects by reducing membrane expression of CaV2.2. Using a rodent model of OA, we demonstrate the intraperitoneal administration of CBD3063 alleviates both evoked and non-evoked behavioral hallmarks of OA pain. Further, we reveal that CBD3063 reduces OA-induced increased neural activity in the parabrachial nucleus, a key supraspinal site modulating the pain experience. Together, these studies suggest CBD3063 is an effective analgesic for OA pain.
Insights
A new drug, CBD3063, effectively treats osteoarthritis pain by targeting the CRMP2 protein to reduce CaV2.2 channel expression. This offers a promising, non-addictive pain relief option without the side effects of current treatments.
Area of Science:
- Neuroscience
- Pharmacology
- Pain Management
Background:
- Osteoarthritis (OA) presents a global pain challenge with limited, side-effect-prone treatments.
- Voltage-gated calcium channels (CaV2.2) are effective pain targets, but associated drugs have administration and side-effect issues.
- Collapsing response mediator protein 2 (CRMP2) is a key regulator of CaV2.2 channels.
Purpose of the Study:
- To investigate CRMP2 as an indirect regulator of CaV2.2 channels for pain treatment.
- To develop and evaluate a CRMP2-modulating peptidomimetic, CBD3063, as an osteoarthritis (OA) analgesic.
- To assess CBD3063's efficacy in reducing OA pain behaviors and neural activity.
Main Methods:
- Development of a CRMP2-targeting peptidomimetic, CBD3063.
- Administration of CBD3063 via intraperitoneal injection in a rodent OA model.
- Assessment of OA pain hallmarks (evoked and non-evoked behaviors) and neural activity in the parabrachial nucleus.
Main Results:
- CBD3063 effectively reversed neuropathic and inflammatory pain by reducing CaV2.2 membrane expression.
- CBD3063 alleviated behavioral signs of OA pain in a rodent model.
- CBD3063 reduced OA-induced neural hyperactivity in the parabrachial nucleus.
Conclusions:
- CBD3063 is a novel, effective analgesic for OA pain.
- Targeting CRMP2 offers a new strategy for modulating CaV2.2 function and treating pain.
- CBD3063 demonstrates potential as a safe and effective OA pain therapeutic.
